![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 27, 20346-20354, July 7, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, March 9, 2000, and in revised form, March 24, 2000
Peroxidases of the peroxiredoxin (Prx) family
contain a Cys residue that is preceded by a conserved sequence in the
NH2-terminal region. A new type of mammalian Prx,
designated PrxV, has now been identified as the result of a data base
search with this conserved Cys-containing sequence. The 162-amino acid
PrxV shares only ~10% sequence identity with previously identified
mammalian Prx enzymes and contains Cys residues at positions 73 and 152 in addition to that (Cys48) corresponding to the conserved
Cys. Analysis of mutant human PrxV proteins in which each of these
three Cys residues was individually replaced with serine suggested that
the sulfhydryl group of Cys48 is the site of oxidation by
peroxides and that oxidized Cys48 reacts with the
sulfhydryl group of Cys152 to form an intramolecular
disulfide linkage. The oxidized intermediate of PrxV is thus distinct
from those of other Prx enzymes, which form either an intermolecular
disulfide or a sulfenic acid intermediate. The disulfide formed by PrxV
is reduced by thioredoxin but not by glutaredoxin or glutathione. Thus,
PrxV mutants lacking Cys48 or Cys152 showed no
detectable thioredoxin-dependent peroxidase activity, whereas mutation of Cys73 had no effect on activity.
Immunoblot analysis revealed that PrxV is widely expressed in rat
tissues and cultured mammalian cells and is localized intracellularly
to cytosol, mitochondria, and peroxisomes. The peroxidase function of
PrxV in vivo was demonstrated by the observations that
transient expression of the wild-type protein, but not that of the
Cys48 mutant, in NIH 3T3 cells inhibited
H2O2 accumulation and activation of c-Jun
NH2-terminal kinase induced by tumor necrosis
factor- Peroxidases of the peroxiredoxin
(Prx)1 family reduce hydrogen
peroxide and alkyl hydroperoxides to water and alcohol, respectively, with the use of reducing equivalents derived specifically from thiol-containing donor molecules such as thioredoxin (Trx) (1, 2), AhpF
(3, 4), and trypanothione (5, 6). More than 40 members of this family
have been identified in a variety of organisms from bacteria to plants
to mammals (7). All Prx proteins contain a conserved cysteine residue
in the NH2-terminal portion of the molecule, and most
contain an additional conserved Cys in the COOH-terminal region. The
COOH-terminal and NH2-terminal Cys residues are separated
by 120-123 amino acids in Prx enzymes from bacteria, yeast, plants,
and mammals, and the sequences surrounding each of these Cys residues
are also highly conserved. A small number of Prx proteins, with
representatives from most phyla, lack the COOH-terminal Cys (8).
Members of the Prx family can thus be divided into two subgroups as
follows: 2-Cys Prx proteins, which contain both the
NH2- and COOH-terminal Cys residues, and 1-Cys Prx
proteins, which contain only the NH2-terminal Cys (8). Members of the 2-Cys Prx subgroup include four mammalian Prx enzymes, PrxI to PrxIV (9-12), that are the products of distinct genes in both
humans and mice. In contrast, only one human and mouse 1-Cys Prx has
been identified (8).
The 2-Cys and 1-Cys Prx enzymes exist as homodimers, with the two
monomers oriented in a head-to-tail manner (13-15). The reaction mechanisms by which 2-Cys and 1-Cys Prx enzymes remove peroxides are
distinct (8). In the case of 2-Cys Prx, peroxides oxidize the
NH2-terminal Cys thiol group (Cys-SH) to sulfenic acid
(Cys-SOH), which immediately reacts with the COOH-terminal Cys-SH of
the other subunit to form an intermolecular disulfide. This disulfide is subsequently reduced specifically by Trx. Thus, mutant 2-Cys Prx
proteins that lack either the NH2-terminal or COOH-terminal Cys residues do not exhibit Trx-coupled peroxidase activity. The NH2-terminal Cys-SH of 1-Cys Prx is also the site of
oxidation by peroxides. However, the resulting Cys-SOH does not form a
disulfide because of the unavailability of another Cys-SH nearby.
Whereas the NH2-terminal Cys is the only Cys residue in the
entire molecule for the mouse 1-Cys Prx, human 1-Cys Prx does contain
an additional Cys; however, mutational analysis indicated that this
latter residue does not participate in the peroxidase reaction (8). The
presence of Cys-SOH in the oxidized human 1-Cys Prx was demonstrated by determination of the crystal structure of the protein (14). The Cys-SOH
of oxidized 1-Cys Prx can be reduced by nonphysiological thiols such as
dithiothreitol (DTT) but not by Trx (8). The physiological electron
donor (or donors) that supports the peroxidase activity of 1-Cys Prx
remains to be identified.
We now describe the identification and characterization of a new type
of mammalian Prx, which forms a reaction intermediate distinct from
those of 2-Cys and 1-Cys Prx enzymes. This new Prx contains the
conserved NH2-terminal Cys as well as two additional Cys
residues, neither of which, on the basis of the sequences surrounding
them and their distances from the NH2-terminal Cys, corresponds to the conserved COOH-terminal Cys of other members of the
Prx family. Thus, this newly identified Prx resembles 1-Cys Prx enzymes
in its primary structure. However, unlike 1-Cys Prx, the new enzyme
forms an intramolecular disulfide intermediate, which is also distinct
from the intermolecular intermediate of 2-Cys Prx.
Materials--
Glutathione reductase was obtained from Roche
Molecular Biochemicals. Trx, Trx reductase (TrxR), and glutaredoxin
(Grx) were prepared as described previously (9). Glutamine synthetase was purified from Escherichia coli as described (1). Tumor necrosis factor- Cloning and Mutation of PrxV--
Searches of a nonredundant
data base of human expressed sequence tags (ESTs) were performed with
TBlastN 2.0 (16). For cloning of the human PrxV cDNA, we performed
the polymerase chain reaction (PCR) with a human liver cDNA library
as template, the forward primer
5'-ATCATATGGCCCCAATCAAGGTGGGAGAT-3', and the reverse primer
5'-TAGAATTCAGAGCTGTGAGATGATATTGG-3' (initiation and stop
codons are indicated in bold). The forward and reverse primers contain
NdeI and EcoRI sites, respectively, at their 5' ends. The PCR product was directly ligated into the mammalian expression vector pCR3.1 (Invitrogen), yielding pCRWT. The nucleotide sequence of the PrxV-coding region was determined by standard automated procedures.
Three mutant human PrxV proteins, C48S, C73S, and C152S, in which
Cys48, Cys73, and Cys152 were
individually replaced by serine, were generated by standard PCR-mediated site-directed mutagenesis with pCRWT as template and
complementary primers containing a single-base mismatch that converted
the codon for Cys to one for Ser. The final mutated PCR products were
also ligated into the pCR3.1 vector, yielding pCRC48S, pCRC73S, and
pCRC152S, respectively. For expression of the wild-type and mutant
proteins in E. coli, the NdeI-EcoRI
fragments of pCRWT and the mutant plasmids were subcloned into the
expression vector pET17b (Novagen), thereby generating pETWT, pETC48S,
pETC73S, and pETC152S.
Expression and Purification of PrxV--
Cells of the E. coli strain BL21(DE3) pLysS (Novagen) were transformed with the
pETWT plasmid, cultured at 37 °C overnight in 100 ml of LB medium
supplemented with ampicillin (100 µg/ml), and then transferred to 10 liters of fresh LB medium in a Microferm Fermentor (New Brunswick
Scientific). When the absorbance of the culture at 600 nm reached
0.6-0.8, isopropyl-
Frozen cells (4 g) were suspended in 20 ml of buffer A (20 mM Hepes-NaOH (pH 7.0), 1 mM EDTA) containing 2 mM DTT and were disrupted by pressure, and the resulting
cell extract was centrifuged at 12,000 × g for 30 min.
Streptomycin sulfate was added to the resulting supernatant to a final
concentration of 1% (w/v), and after 30 min at 4 °C, the mixture
was centrifuged at 12,000 × g for 30 min. Solid
ammonium sulfate was slowly added, at 4 °C with stirring, to the
resulting supernatant until 80% saturation was achieved, after which
the mixture was stirred for an additional 1 h. The resulting
precipitate was collected by centrifugation at 15,000 × g for 30 min and dissolved in 10 ml of buffer A containing 2 mM DTT and 0.5 M
(NH4)2SO4. Insoluble material was
removed by centrifugation at 15,000 × g for 30 min,
and the resulting supernatant was fractionated by high performance
liquid chromatography (HPLC) on a TSK phenyl 5PW column (21.5 by 150 mm) that had been equilibrated with buffer A containing 1.5 M (NH4)2SO4. Proteins
were eluted with a decreasing gradient of ammonium sulfate from 1.5 to
0 M over 60 min at a flow rate of 5 ml/min. Fractions of 5 ml were collected, and those (fractions 28-32) corresponding to the
peak of PrxV were pooled, dialyzed against 2 liters of buffer B (20 mM Tris-HCl (pH 7.5), 1 mM EDTA), and
concentrated in an Amicon concentrator. The concentrated sample was
reduced with 2 mM DTT for 10 min and applied to a Mono Q
HR10/10 column (Amersham Pharmacia Biotech) that had been equilibrated
with buffer B. The column was washed with the same buffer for 10 min.
PrxV was detected in the flow-through material, and those fractions
containing the protein were pooled, dialyzed against 2 liters of buffer
A, and stored at Assay of PrxV Activity--
The ability of PrxV to protect
glutamine synthetase from oxidative inactivation was measured as
described previously (1), with a slight modification. The 25-µl
reaction mixture, containing 0.5 µg of glutamine synthetase, 10 mM DTT, 3 µM FeCl3, 50 mM Hepes-NaOH (pH 7.0), and various concentrations of PrxV,
was incubated at 37 °C for 10 min, after which 1 ml of
Subcellular Fractionation--
HeLa cells that had been grown to
confluency in Dulbecco's modified Eagle's medium supplemented with
10% fetal bovine serum were washed twice with ice-cold
phosphate-buffered saline. The washed cells were disrupted in a
homogenization buffer (10 mM triethanolamine, 10 mM acetic acid (pH 7.4), 250 mM sucrose, 1 mM EDTA, 1 mM DTT, and aprotinin, leupeptin,
pepstatin, and chymostatin each at a concentration of 10 µg/ml) by
passing them 10 times through a 25-gauge needle, followed by
homogenization in a Dounce homogenizer. Nuclei and unbroken cells were
removed by centrifugation of the homogenate at 1000 × g for 10 min. The resulting supernatant was further
centrifuged sequentially at 14,000 × g for 30 min to
separate organelles and at 100,000 × g for 1 h to
obtain plasma membrane and cytosolic fractions.
Transfection--
NIH 3T3 cells were cultured in Dulbecco's
modified Eagle's medium supplemented with 10% calf serum, penicillin
(100 units/ml), and streptomycin (100 units/ml) and were continuously
passaged for 3 months after thawing. For transfection, the cells were
plated at a density of 3 × 105 per 60-mm dish,
allowed to recover for 24 h, and then transfected with the
indicated plasmids with the use of Superfect (Qiagen). After 24 h,
the cells were deprived of serum by incubation for an additional
18 h in the presence of 0.5% calf serum and then subjected to the experiments.
Cloning and Purification of Recombinant PrxV--
The amino acid
sequence identity among the four human 2-Cys Prx (PrxI to PrxIV)
enzymes is >70%, with the homology being especially marked in the
regions surrounding the conserved NH2- and COOH-terminal Cys residues that correspond to Cys52 and
Cys173 of PrxI (Fig. 1). The
human 1-Cys Prx shares ~10% amino acid sequence identity with human
2-Cys Prx enzymes, but the sequence surrounding its
NH2-terminal Cys (Cys47) is highly homologous
to those surrounding the corresponding Cys of 2-Cys Prx enzymes (Fig.
1).
In an attempt to identify new Prx enzymes, we searched a data base of
human ESTs for sequences homologous to the NH2-terminal conserved sequence (KGKYVVLFFYPLDFTFVCP) of 2-Cys Prx enzymes. A human
EST clone (GenBankTM accession number, H26194) with a
Cys-containing sequence
(KGKKGVLFGVPGAFTPGCS) that shares 52% identity (indicated in bold) with the search sequence was thus detected. With the use of the nucleotide sequence of this
clone, 87 EST clones containing identical overlapping sequences were
further identified. We aligned all of these sequences in advanced BLAST
searches and then constructed a 767-base pair nucleotide sequence that
includes a Kozak consensus sequence for translation initiation, an open
reading frame encoding a 162-amino acid polypeptide, a stop codon (TGA)
in the same frame, and a 135-base pair 3'-untranslated sequence
containing a poly(A) tract. The newly identified putative Prx enzyme
encoded by this nucleotide sequence was designated PrxV for reasons
described below. Similar searches of a mouse EST data base with the
same NH2-terminal conserved sequence of 2-Cys Prx enzymes
also revealed a clone (GenBankTM accession number,
AA472012) with a Cys-containing sequence that is identical to the
corresponding portion of the human PrxV sequence. Identification of
clones containing overlapping sequences yielded an open reading frame
for a 162-amino acid protein that shows 95% sequence identity to human
PrxV (Fig. 1).
Human PrxV is ~10% identical to human 2-Cys and 1-Cys Prx enzymes
(Fig. 1). The COOH-terminal region of PrxV is smaller than those of
2-Cys Prx enzymes and lacks the conserved sequence containing the
COOH-terminal Cys of the latter enzymes. Both human and mouse PrxV
sequences contain Cys residues at positions 73 and 152 in addition to
the conserved Cys48. However, the sequences surrounding
Cys73 and Cys152 are not homologous to those
surrounding the COOH-terminal conserved Cys residue of 2-Cys Prx
enzymes, and the distances between Cys48 and these other
two Cys residues are substantially smaller than the 120-123 residues
that separate the two conserved Cys residues in typical 2-Cys Prx
enzymes. PrxV shows 30% sequence identity to a Saccharomyces
cerevisiae Prx known as type II Trx-dependent peroxidase (18) or peroxisomal membrane protein 20 (PMP20) (19) or
alkyl hydroperoxide reductase (20); however, the yeast protein does not
contain Cys residues corresponding to Cys73 and
Cys152 of PrxV.
Human PrxV was expressed in E. coli and purified to
homogeneity. The purified protein appeared as a single band with an
apparent molecular size of 17 kDa on SDS-PAGE under reducing conditions (not shown), consistent with the size of 17,030 Da calculated from the
predicted amino acid sequence. PrxV that had been oxidized with
H2O2 was also detected as a monomer by SDS-PAGE
under either reducing or nonreducing conditions (Fig.
2A), suggesting that the
protein does not form a disulfide-linked dimer on oxidation by
H2O2. HPLC of PrxV on a gel filtration column
in the presence of a buffer containing DTT yielded a peak at a position
corresponding to 34 kDa (Fig. 2B), suggesting that PrxV
exists as a dimer in its native state.
Trx-dependent Peroxidase Activity of PrxV--
We
investigated whether the reducing equivalents required for the presumed
peroxidase activity of PrxV could be provided by the Trx system (Trx,
TrxR, and NADPH) or the Grx system (Grx, GSH, GSH reductase, and
NADPH). The rate of H2O2 degradation was measured by monitoring the decrease in A340
attributable to the oxidation of NADPH. PrxV catalyzed the
H2O2-dependent oxidation of NADPH
in the presence of the Trx system (Fig.
3); the oxidation of NADPH required all
three protein components (PrxV, Trx, and TrxR), being negligible in the
absence of any one of the three. In contrast, the Grx system did not
support the H2O2-dependent oxidation of NADPH by PrxV. Increasing the concentrations of Grx, GSH,
and GSH reductase severalfold relative to those specified in the legend
to Fig. 3 did not affect the inability of the Grx system to support the
peroxidase activity of PrxV (data not shown). The functional efficacy
of the Grx and GSH reductase preparations was demonstrated as described
previously (21). These results suggest that PrxV receives reducing
equivalents readily from Trx but not from Grx or from millimolar
concentrations of GSH. PrxV also reduced t-butyl
hydroperoxide in the presence of the Trx system with initial rates
similar to that apparent for H2O2 reduction (data not shown).
Kinetic parameters for PrxV catalysis were determined by
measuring the initial rates of NADPH oxidation at various
concentrations of Trx and H2O2. Lineweaver-Burk
plots (not shown) revealed that the Km values of
PrxV for Trx and H2O2 were 1 and <20 µM, respectively, and that the
Vmax at 37 °C was 2 or 2.8 µmol/min/mg of
protein for the experiments in which the concentrations of Trx and
H2O2, respectively, were varied.
Peroxidase Activity of Cys Mutants of PrxV--
To study the
catalytic role of the Cys residues of PrxV, we replaced each of the
three residues at positions 48, 73, and 152 individually with serine,
thereby generating C48S, C73S, and C152S mutant enzymes, respectively.
The mutant proteins were expressed in E. coli and purified
to homogeneity (Fig. 4A).
Measurement of Trx-dependent peroxidase activity toward
H2O2 revealed that the activity of the C73S
mutant was similar to that of the wild-type enzyme, whereas no activity
was detected with C48S and C152S proteins (Fig. 4B).
We also evaluated the peroxidase activities of the mutants by measuring
their ability to protect glutamine synthetase from inactivation induced
by a low concentration of H2O2 produced by a
mixed function oxidation system comprising O2, DTT, and
iron. In the presence of an electron donor such as DTT, iron catalyzes the reduction of O2 to H2O2, which
is further converted to hydroxyl radicals (OH·) by the Fenton
reaction (22). Glutamine synthetase possesses a binding site for
divalent cations, at which bound iron catalyzes OH· production.
The locally produced OH· results in oxidation and consequent
inactivation of the enzyme (22). Given that oxidized Prx can be reduced
by DTT, Prx prevents the inactivation of glutamine synthetase by the
mixed function oxidation system through removal of
H2O2. We have previously used this glutamine
synthetase protection assay for the detection of Prx activity,
especially when we did not know the physiological source of the
reducing equivalents (1, 8). Consistent with the results of the
Trx-dependent assay, C48S was completely inactive in the
glutamine synthetase protection assay, and the activity of C73S was
equal to or slightly higher than that of wild-type PrxV (Fig.
4C). However, in contrast to the results obtained with the
Trx-dependent assay, C152S protected glutamine synthetase, albeit less effectively than did the wild-type protein. These data
suggest that Cys48 is essential for both Trx- and
DTT-dependent peroxidase activities of PrxV, that
Cys73 is not required for either of these two activities,
and that Cys152 is essential for Trx-dependent
activity but not for DTT-dependent activity.
Formation of a Disulfide Bond between Cys48 and
Cys152 of PrxV--
We next examined the possibility that
Cys48 and Cys152 form a disulfide bond during
the catalytic cycle of PrxV. PrxV that had been oxidized by
H2O2 was digested with endopeptidase Lys-C, and the resulting peptides were fractionated by HPLC on a C18
column (Fig. 5, upper panel).
Reduction of a portion of the Lys-C digest with DTT before HPLC
resulted in the disappearance of peak I that was detected with the
unreduced sample (not shown), suggesting that peak I likely contained
peptides linked by a disulfide. Treatment with DTT of the manually
collected peak I fraction followed by reinjection into the HPLC column
yielded peaks II and III (Fig. 5, middle panel). Edman
sequencing of the peptides corresponding to these latter two peaks
yielded the sequences GVLFG and ALNVE, respectively, that match the
five residues of the predicted Lys-C fragments containing
Cys48 and Cys152, respectively. We also
prepared a Lys-C digest of oxidized PrxV that had been exposed to
5,5'-dithiobis-2-nitrobenzoic acid; fractionation of the digest by
HPLC, with monitoring of elution of 5-thio-2-nitrobenzoic acid-labeled
peptides by measurement of A328, revealed only
one major labeled peak (peak IV) (Fig. 5, lower panel). The
sequence of the peptide contained in peak IV was determined to be
GVQVVA, which matches the first six residues of the
Cys73-containing Lys-C peptide of PrxV. These results
indicate that oxidation of PrxV by H2O2 results
in the formation of a disulfide between Cys48 and
Cys152, whereas Cys73-SH remains
unoxidized.
Tissue, Cellular, and Subcellular Distribution of PrxV--
Total
soluble fractions prepared from various rat tissues and cultured
mammalian cells were subjected to immunoblot analysis with rabbit
antibodies specific for PrxV (Fig. 6).
Only one immunoreactive protein of 17 kDa was detected for all tissues
and cells. Comparison of the blot intensities of this endogenous
protein with those of various amounts of purified PrxV allowed us to
estimate the amount of PrxV in micrograms per milligram of total
soluble protein. The amounts of PrxV in rat tissues and cultured
mammalian cells are shown together with those of other Prx enzymes in
Tables I and
II, respectively. Similar to other Prx
isoforms, PrxV was expressed in almost all tissues and cell lines
examined; it is especially abundant in kidney and kidney-derived KNRK
cells, contributing as much as 0.13% of total soluble protein.
We next investigated the subcellular localization of PrxV by immunoblot
analysis. HeLa cell homogenates were separated into organellar, plasma
membrane, and cytosolic fractions. PrxV was detected in organellar and
cytosolic fractions in a ratio of ~2:1 but was not detected in the
plasma membrane fraction (Fig.
7A). The molecular size of
PrxV detected in cytosolic and organellar fractions was identical at 17 kDa. Further fractionation of the organellar fraction on Nycodenz
gradients (23) revealed that the distribution of PrxV was similar to
that of the mitochondrial protein PrxIII but not to that of the
peroxisomal protein catalase, suggesting that most PrxV in the
organellar fraction is present in mitochondria (data not shown). The
presence of PrxV in peroxisomes was further investigated by immunoblot
analysis of a peroxisomal fraction prepared from guinea pig liver. PrxV
and catalase, but neither PrxIII nor the cytosolic enzyme PrxII, were
detected in this fraction (Fig. 7B), which has been
previously characterized by Webber and Hajra (24).
Peroxidase Activity of PrxV in Intact Cells--
Stimulation of
NIH 3T3 cells with PDGF or TNF-
The increase in intracellular H2O2 results in
the activation of JNK (25, 26). We therefore examined the effect of
PrxV overexpression on the activation of HA-tagged JNK. TNF- We have shown that PrxV catalyzes the reduction of
H2O2 both in vitro and in
vivo and that Trx is likely the specific donor of the reducing
equivalents required for the reduction reaction. Neither Grx nor GSH
was able to support the peroxidase activity of PrxV. The simplest
reaction mechanism for PrxV that is compatible with the observations
that both Cys48 and Cys152 are essential for
Trx-dependent activity and that the oxidized intermediate
is a monomer containing the Cys48-Cys152
disulfide is shown in Fig.
10A. The C48S mutant of PrxV
is inactive regardless of whether the reducing equivalents are provided
by DTT or by Trx, whereas the C152S mutant is active in the presence of
DTT but not in the presence of the Trx system. These results suggest
that Cys48 is the primary site of substrate peroxide
reduction and is directly oxidized by H2O2 to
yield H2O and Cys48-SOH; the latter reacts with
Cys152-SH to form an intramolecular disulfide, which is
subsequently reduced by Trx. In this model, Cys48-SOH would
react with one thiol of DTT to form a mixed disulfide in the absence of
Cys152, whereas the second thiol of DTT would attack the
disulfide to produce Cys48-SH and oxidized DTT (Fig.
10B). Such a mechanism would explain why the C152S mutant
protects glutamine synthetase from oxidation by the DTT-containing
mixed function oxidation system, albeit with an efficiency lower than
that of the wild-type protein.
The mechanisms of 2-Cys and 1-Cys Prx enzymes are shown in Fig. 10,
C and D, respectively. The four mammalian members
(PrxI to PrxIV) of the 2-Cys Prx subgroup form intermediates that
contain an intermolecular disulfide between the NH2- and
COOH-terminal Cys residues that correspond to Cys52 and
Cys173, respectively, of human PrxI. The two
disulfide-forming Cys residues of 2-Cys Prx enzymes are separated by
121 amino acids, whereas those of PrxV are separated by 104 residues.
Moreover, the amino acid sequence surrounding Cys152 of
PrxV does not resemble that surrounding Cys173 of PrxI. In
human 1-Cys Prx, the NH2-terminal Cys (Cys47)
is the site of oxidation by H2O2, but the
resulting Cys-SOH cannot form a disulfide because there is no other
Cys-SH nearby. Although the physiological source of the reducing
equivalents for the regeneration of Cys47-SH is not
known,2 DTT is
able to support the regeneration in vitro. In this respect, the reaction mechanism of 1-Cys Prx resembles that of the C152S mutant
of PrxV. The crystal structures of oxidized 1-Cys Prx (14) and PrxII
(15) have revealed that both enzymes exist as head-to-tail dimers, in
which the larger NH2-terminal domain of one subunit folds
over the smaller COOH-terminal domain of the other subunit to form an
active site. The presence of Cys-SOH in the active site of 1-Cys Prx
and of an intermolecular disulfide in the active site of PrxII was
apparent. The reactive Cys of 1-Cys Prx is located at the bottom of the
active site pocket and is thus protected from larger oxidant molecules
that contain a disulfide. Whether PrxV forms a similar head-to-tail
dimer remains to be determined.
The catalytic efficiency of PrxV is similar to those of 2-Cys Prx
enzymes as follows: the Vmax of 2.0-2.8 µ mol/min/mg of protein for PrxV is smaller than those of 6-13
µmol/min/mg of protein for PrxI, PrxII, and PrxIII, but the
Km for Trx of 1 µM for PrxV is also
smaller than those of 3-6 µM for the 2-Cys Prx enzymes
(12). The Km for H2O2 is
<20 µM for PrxV and 2-Cys Prx enzymes. The catalytic
efficiency of 1-Cys Prx has not been evaluated because its
physiological donor of reducing equivalents is not known.
While the present study was in progress, PrxV was identified as
proteins designated PMP20 and antioxidant enzyme B166 (AOEB166). Yamashita et al. (19) cloned human and mouse PMP20 cDNAs
as the result of a search for homologs of the yeast PMP20 protein, and
Knoops et al. (27) cloned human and rat AOEB166 cDNAs as the result of an attempt to characterize a 17-kDa bronchoalveolar protein. Mammalian PMP20 proteins consist of 162 amino acids and contain a peroxisomal targeting sequence (Ser-Gln-Leu) at the COOH
terminus, as does PrxV (Fig. 1). The peroxisomal localization of PMP20
was demonstrated by expressing HA-tagged PMP20 in HeLa cells and
immunostaining with antibodies to the HA tag. Knoops et al.
(27) observed that the AOEB166 cDNA contains two potential initiation sites in the same reading frame, the use of one would result
in the production of a 162-residue protein identical to PrxV (PMP20),
and the use of the other would generate a polypeptide of 214 residues.
The 52 amino acid residues at the NH2 terminus of the
longer polypeptide were shown to constitute a mitochondrial presequence
that is capable of importing a fusion protein of AOEB166 and green
fluorescent protein into mitochondria (27). Yamashita et al.
(19) and Knoops et al. (27) demonstrated that the
bacterially expressed 162-residue PMP20 (AOEB166) protein is able to
protect glutamine synthetase from the DTT-containing mixed function
oxidation system. Recognizing that AOEB166 is homologous (25-35%
sequence identity) to yeast and bacterial members of the Prx family and that four mammalian Prx enzymes had been identified previously, Knoops
et al. (27) renamed the protein PrxV. Although PrxV is distantly related to PrxI to PrxIV (showing only 10% sequence identity), does not contain the COOH-terminal Cys conserved in 2-Cys
Prx enzymes, and forms a distinct reaction intermediate, we believe
that PrxV is an appropriate designation because the protein is a
Trx-dependent enzyme whose function is dependent on two Cys residues.
With the use of immunoblot analysis with antibodies specific for PrxV,
we estimated the amounts of PrxV in various rat tissues and cultured
mammalian cells and compared them with the amounts of PrxI, PrxII,
PrxIII, and 1-Cys Prx. The relative abundance of PrxV protein among rat
tissues was not in good agreement with the relative abundance of PMP20
or AOEB166 mRNAs as determined by Northern blot analysis. Like the
other Prx enzymes, PrxV is widely expressed, with an abundance of
0.2-1.3 µg/mg of soluble protein in the 13 rat tissues examined.
Immunoblot analysis of subcellular fractions derived from HeLa cells
and guinea pig liver revealed the presence of PrxV in cytosol,
mitochondria, and peroxisomes, consistent with previous observations on
the subcellular distribution of HA-tagged PMP20 and the AOEB166-green
fluorescent protein fusion construct. The molecular size of PrxV in all
tissues and cell lines examined as well as in the three subcellular
fractions was identical to that of the 162-residue recombinant
polypeptide. These observations, together with the results obtained
with AOEB166, suggest that mitochondrial PrxV is synthesized in the
cytosol from the first initiation site of PrxV mRNA as a
214-residue precursor protein and imported into mitochondria, where it
is converted to the mature form with a size that is indistinguishable
from that of the cytosolic and peroxisomal enzymes. Both of the latter are likely translated as 162-residue proteins from the second initiation site of PrxV mRNA.
Mitochondria and peroxisomes are the major source of
H2O2 production in unstimulated mammalian
cells. Molecular oxygen is reduced by electrons that leak from the
mitochondrial respiratory chain to form the superoxide anion, which
then undergoes spontaneous or enzyme-mediated dismutation to
H2O2. Peroxisomes contain several enzymes that
catalyze the oxidation of organic substrates such as fatty acids and
D-amino acids and thereby generate
H2O2. Mitochondria and peroxisomes are equipped
with PrxIII and catalase, respectively, to protect against the toxic
effects of H2O2. PrxV can now be added to the
known antioxidant enzymes that protect these two oxidant-generating
organelles. As predicted from the long mitochondrial targeting sequence
at its NH2 terminus, PrxIII is synthesized in the cytosol
as a preprotein that is converted to the mature form in mitochondria
(28). The reducing equivalents required for the reactions of PrxIII and
PrxV are likely provided by the recently discovered mitochondria-
specific proteins Trx (29) and TrxR (30), both of which are also
synthesized in the cytosol with mitochondrial targeting sequences.
Whether peroxisomes also contain a specific Trx system for PrxV remains
to be determined. PrxI, PrxII, and 1-Cys Prx are localized
predominantly to the cytosol, and PrxIV, which contains a typical
signal sequence of secretory proteins at its NH2 terminus,
is secreted outside of cells (11).
In many mammalian cell types, H2O2 is produced
in response to a variety of extracellular stimuli that include TNF- We thank N. Holbrook for providing the
plasmid for GST-c-Jun; J. M. Kyriakis for the plasmid for
HA-tagged JNK; T.-W. Kim for subcellular fractionation of HeLa cells;
and A. Hajra for guinea pig liver peroxisomes.
*
This work was supported in part by a grant (to K. K.) from
the Korea Science and Engineering Foundation through the Center for
Cell Signaling Research of Ewha Women's University.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Both authors contributed equally to this work.
¶
Present address: Dept. of Pharmacology, College of Medicine,
Catholic Neuroscience Center, Catholic University of Korea, Seoul 137-701, Korea.
§§
To whom correspondence should be addressed: Bldg. 3, Rm. 120, National Institutes of Health, Bethesda, MD 20892. Tel.: 301-496-9646; Fax: 301-480-0357; E-mail: rheesg@nhlbi.nih.gov.
Published, JBC Papers in Press, April 4, 2000, DOI 10.1074/jbc.M001943200
2
Glutathione has been suggested to be the
physiological donor for 1-Cys Prx (35). However, we (8) and others (36)
failed to detect GSH-supported peroxidase activity of 1-Cys-Prx.
The abbreviations used are:
Prx, peroxiredoxin;
Trx, thioredoxin;
DTT, dithiothreitol;
TrxR, Trx reductase;
Grx, glutaredoxin;
TNF-
Identification of a New Type of Mammalian Peroxiredoxin That
Forms an Intramolecular Disulfide as a Reaction Intermediate*
§¶,
§,
,

, and
§§
Laboratory of Cell Signaling and
** Department of Extramural Affairs, NHLBI, National Institutes of
Health, Bethesda, Maryland 20892 and the
Department of Food
and Nutrition, Chonnam National University,
Kwangju 500-757, Korea
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(TNF-
) and platelet-derived growth factor
(PDGF)-AB were obtained from Life Technologies, Inc., and Upstate
Biotechnology, Inc., respectively. Rabbit polyclonal antibodies to
recombinant PrxV were produced by standard immunization procedures. An
E. coli expression plasmid encoding a glutathione
S-transferase (GST) fusion protein of c-Jun, a plasmid
encoding hemagglutinin epitope (HA)-tagged c-Jun
NH2-terminal kinase (JNK), and peroxisomes isolated from
guinea pig liver were kindly provided by N. Holbrook (NIA, National
Institutes of Health), J. M. Kyriakis (Harvard Medical School),
and A. Hajra (Department of Biological Chemistry, University of
Michigan), respectively. Antibodies to PrxII and PrxIII were prepared
as described (9).
-D-thiogalactopyranoside was added
to a final concentration of 0.4 mM. After incubation for an
additional 3 h, the cells were collected by centrifugation, frozen
in liquid nitrogen, and stored at
70 °C until use. The recombinant
PrxV protein was present in the soluble fraction of the bacterial cells
(data not shown) and was monitored during purification by
SDS-polyacrylamide gel electrophoresis (PAGE) and staining with
Coomassie Blue.
70 °C until use. The mutant C48S, C73S, and C152S
proteins were prepared by a procedure similar to that used for the
wild-type enzyme.
-glutamyltransferase assay mixture was added and the remaining
activity of glutamine synthetase was measured at 37 °C for 3 min.
The Trx-dependent peroxidase activity of PrxV was measured
as described (17).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (57K):
[in a new window]
Fig. 1.
Alignment of the amino acid sequences of
human PrxV (hPrxV) and mouse PrxV (mPrxV) with human 2-Cys (PrxI to
PrxIV) and 1-Cys Prx proteins. The alignment was obtained by
Clustal X (version 1.8) (37). Dashes within sequences
represent gaps introduced to optimize alignment. Residue numbers are
shown on the right. The positions of the
NH2-terminal Cys residue conserved in all Prx members
(square), of the COOH-terminal Cys residue conserved in
2-Cys Prx enzymes (PrxI to PrxIV) (circle), and of
Cys73 and Cys152 of PrxV (triangles)
are indicated and boxed. The NH2-terminal
52-residue sequence shown to include the mitochondrial targeting
sequence of a PrxV preprotein (27) is not shown.

View larger version (8K):
[in a new window]
Fig. 2.
SDS-PAGE and HPLC gel filtration analysis of
recombinant human PrxV purified from E. coli.
A, purified PrxV (10 µg in 20 µl) that had been oxidized
with 0.1 mM H2O2 for 5 min was
mixed with 20 µl of reducing sample buffer (125 mM
Tris-HCl (pH 6.8), 4% (w/v) SDS, 20% (v/v) glycerol, 10 mM DTT) (lane 1) or nonreducing sample buffer
(reducing sample buffer minus DTT) (lane 2), heated at
95 °C for 5 min, subjected to SDS-PAGE on a 14% gel, and stained
with Coomassie Brilliant Blue. The positions of molecular size markers
(in kilodaltons) are indicated on the left. B,
purified PrxV was applied to a Superose 12 PC 3.2/30 column (3.2 300 mm, Amersham Pharmacia Biotech) on an Amersham Pharmacia Biotech SMART
System equipped with µ separation unit and µ precision pump. The
proteins were eluted at the flow rate of 40 µl/min with 20 mM Tris-HCl (pH 7.5) containing 150 mM NaCl.
Fractions of 40 µl were collected during monitoring by measurement of
A280. The peak positions of molecular size
markers are indicated.

View larger version (14K):
[in a new window]
Fig. 3.
NADPH oxidation coupled to the peroxidase
activity of PrxV in the presence of the Trx or Grx systems. The
initial rate of NADPH oxidation was monitored by measurement of the
decrease in A340 in the presence of PrxV at
37 °C. The 150-µl reaction mixture contained 50 mM
Hepes-NaOH (pH 7.0), 250 µM NADPH, 1.5 µM
PrxV, and either 46 nM TrxR (squares), 2.2 µM Trx (triangles), both 46 nM
TrxR and 2.2 µM Trx (closed circles), or the
Grx system (46 nM GSH reductase, 2.2 µM Grx,
2 mM GSH) (open circles). The reaction was
initiated by the addition of 0.5 mM
H2O2.

View larger version (14K):
[in a new window]
Fig. 4.
Effects of replacement of Cys48,
Cys73, or Cys152 of PrxV with serine on
peroxidase activity. A, purified recombinant wild-type
(WT) or mutant PrxV proteins (2 µg per lane) were treated
with a reducing sample buffer containing 5 mM DTT and then
analyzed by SDS-PAGE on a 14% gel. The positions of molecular size
markers (in kilodaltons) are indicated on the left.
B, initial rates of NADPH oxidation coupled to
Trx-dependent peroxidase activity of PrxV enzymes were
monitored by measurement of A340 in a 150-µl
reaction mixture containing 50 mM Hepes-NaOH (pH 7.0), 250 µM NADPH, 1.5 µM PrxV, 46 nM
TrxR, and 2.2 µM Trx. Data are expressed as nanomoles of
NADPH oxidized per min. C, glutamine synthetase protection
activities of the indicated concentrations of wild-type PrxV
(triangles), C48S (squares), C73S
(circles), and C152S (diamonds) were measured as
described under "Experimental Procedures." Quantitative data in
B and C are representative of three independent
experiments.

View larger version (22K):
[in a new window]
Fig. 5.
Isolation of Cys-containing peptides from
Lys-C digests of PrxV. Upper panel, purified
recombinant PrxV (200 µg) that had been oxidized with 0.1 mM H2O2 for 5 min was denatured
with an unfolding buffer (6 M guanidine HCl, 1 mM EDTA, 0.1 M potassium phosphate (pH 7.0))
and precipitated by 10% (w/v) trichloroacetic acid. The precipitate
was resuspended in 300 µl of 10 mM Tris-HCl (pH 8.0)
containing 10% (v/v) acetonitrile and digested with Lys-C (4 µg)
overnight. The resulting peptides were applied to an HPLC
C18 column and were eluted with a linear gradient of
0-60% acetonitrile in 0.1% trifluoroacetic acid over 60 min.
Elution was monitored by measurement of A210.
Peak I was collected. Middle panel, HPLC analysis of
peptides derived from peak I after reduction with DTT. Lower
panel, PrxV (200 µg) was oxidized with
H2O2, labeled with 5-thio-2-nitrobenzoic acid
by treatment with unfolding buffer containing 5 mM
5,5'-dithiobis-2-nitrobenzoic acid, and precipitated by 10%
trichloroacetic acid. The precipitated protein was digested with Lys-C
and analyzed by HPLC on the C18 column. Elution was
monitored by measurement of both A210 and
A328.

View larger version (57K):
[in a new window]
Fig. 6.
Immunoblot analysis of PrxV expression in
various rat tissues and cultured mammalian cells. Total soluble
fractions (30 µg of protein) of rat tissues (upper panel)
or cultured mammalian cells (lower panel) were prepared as
described (12) and subjected to SDS-PAGE on 14% gels. The separated
proteins were transferred to a nitrocellulose membrane and probed with
antibodies specific for PrxV. The first four lanes of each
panel contain the indicated amounts of purified PrxV. Immune complexes
were visualized with the use of alkaline phosphatase-conjugated goat
antibodies to rabbit immunoglobulin G. Cell lines examined included
human epithelioid carcinoma HeLa cells, mouse NIH 3T3 fibroblasts,
human epidermoid carcinoma A431 cells, rat embryonic thoracic aorta
smooth muscle A10 cells, human chronic myelogenous leukemia K562 cells,
human histiocytic lymphoma U937 cells, human Burkitt's lymphoma Ramos
cells, human T cell leukemia Jurkat cells, human hepatocellular
carcinoma HepG2 cells, rat thyroid FRTL cells, rat kidney KNRK cells,
and rat adrenal pheochromocytoma PC12 cells.
Amounts of various Prx isoforms in the indicated rat tissues
Amounts of various Prx isoforms in the indicated cultured mammalian
cells

View larger version (12K):
[in a new window]
Fig. 7.
Subcellular distribution of PrxV.
A, the postnuclear supernatant (lane 1),
organellar fraction (lane 2), plasma membrane fraction
(lane 3), and cytosolic fraction (lane 4) of HeLa
cells were subjected to immunoblot analysis with rabbit antibodies to
PrxV. B, immunoblot analysis of a peroxisomal fraction of
guinea pig liver with antibodies to either PrxV, PrxIII, PrxII, or
catalase. Lane 1 contains protein standards; lanes
2-4 contain 10, 20, and 40 µg, respectively, of peroxisomal
proteins.
increases the intracellular
concentration of H2O2, which can be monitored with the oxidation-sensitive fluorescent probe
2',7'-dichlorofluorescein diacetate and confocal microscopy. To
determine whether PrxV is a physiologically relevant peroxidase in
cells, we transiently transfected NIH 3T3 cells, which contain a
relatively low amount of endogenous PrxV (Table II), with expression
vectors encoding wild-type or C48S mutant proteins. Overexpression of
the PrxV proteins was confirmed by immunoblot analysis (Fig.
8A). Exposure of cells
transfected with the empty vector to TNF-
(15 ng/ml) for 10 min or
PDGF (10 ng/ml) for 5 min resulted in 4.5- and 3.5-fold increases,
respectively, in the fluorescence of 2',7'-dichlorofluorescein (DCF)
(Fig. 8B). Expression of wild-type PrxV, but not that of C48S, markedly inhibited both the TNF-
- and PDGF-induced increases in DCF fluorescence.

View larger version (14K):
[in a new window]
Fig. 8.
Effect of PrxV overexpression on
H2O2 generation in response to
TNF-
or PDGF-AB. A, NIH 3T3
cells were transiently transfected with 10 µg of the indicated PrxV
expression plasmids (pCR represents the empty pCR3.1 vector), and the
extent of PrxV expression was measured by immunoblot analysis of cell
lysates (20 µg of protein). B, the transfected cells were
incubated either for 10 min with TNF-
(15 ng/ml) or for 5 min with
PDGF-AB (10 ng/ml), after which relative DCF fluorescence intensity per
cell was measured by confocal microscopy (9). Data are means ± S.E. of values obtained from five random groups of 20-30 cells and are
representative of three independent experiments.
induced a 2-fold increase in JNK activity in NIH 3T3 cells that had been transfected with the empty vector, and this effect of TNF-
was partially inhibited by expression of wild-type PrxV but not by expression of C48S (Fig. 9).

View larger version (13K):
[in a new window]
Fig. 9.
Effect of PrxV overexpression on
TNF-
-induced activation of JNK.
A, NIH 3T3 cells were transiently cotransfected with a
reporter plasmid encoding HA-JNK (3 µg) and the indicated PrxV
expression plasmids (6 µg). Cells were stimulated with TNF-
(15 ng/ml), and the activity of JNK was assayed with GST-c-Jun as substrate
as described (38). The top panel represents an autoradiogram
showing the phosphorylation of GST-c-Jun. The middle and
bottom panels represent immunoblot analysis of cell lysates
with antibodies to JNK1 and PrxV, respectively. B, the
radioactivity associated with the GST-c-Jun bands in the autoradiogram
shown in the upper panel of A was quantitated by
PhosphorImager analysis and expressed relative to the value for
non-stimulated pCR3.1-transfected cells. Similar results were obtained
from four independent experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (18K):
[in a new window]
Fig. 10.
Comparison of the peroxidase reaction
mechanisms. Proposed reaction mechanisms of wild-type PrxV
supported by Trx (A), the C152S mutant of PrxV supported by
DTT (B), PrxI (representative of 2-Cys Prx enzymes)
supported by Trx (C), and 1-Cys Prx supported by DTT or
XH2, the as yet unidentified electron donor for
1-Cys Prx (D), are shown. Closed circles indicate
the NH2 terminus of each protein.
(31) and PDGF (32). This receptor-mediated generation of
H2O2 in the cytoplasm has been linked to
various intracellular signaling events such as the activation of
mitogen-activated protein kinases (32) and the triggering of apoptosis
(33, 34). Specific inhibition of such H2O2
accumulation prevents these receptor-mediated signaling events.
Overexpression of wild-type PrxV, but not that of the
peroxidase-defective mutant C48S, inhibited
H2O2 accumulation induced by TNF-
or PDGF as
well as the TNF-
-induced activation of JNK in NIH 3T3 cells,
suggesting that cytosolic PrxV likely participates in the signaling
pathways of these extracellular stimuli.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES

Present address: Korea Research Institute of Bioscience and
Biotechnology, Yusong, Taejon 305-600, Korea.
![]()
ABBREVIATIONS
, tumor necrosis factor-
;
PDGF, platelet-derived growth factor;
GST, glutathione
S-transferase;
HA, hemagglutinin epitope;
JNK, c-Jun
NH2-terminal kinase;
EST, expressed sequence tag;
PCR, polymerase chain reaction;
PAGE, polyacrylamide gel electrophoresis;
HPLC, high performance liquid chromatography;
DCF, 2'7'-dichlorofluorescein.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Kim, K.,
Kim, I. H.,
Lee, K. Y.,
Rhee, S. G.,
and Stadtman, E. R.
(1988)
J. Biol. Chem.
263,
4704-4711
2.
Chae, H. Z.,
Chung, S. J.,
and Rhee, S. G.
(1994)
J. Biol. Chem.
269,
27670-27678
3.
Storz, G.,
Jacobson, F. S.,
Tartaglia, L. A.,
Morgan, R. W.,
Silveira, L. A.,
and Ames, B. N.
(1989)
J. Bacteriol.
171,
2049-2055
4.
Li Calzi, M.,
and Poole, L. B.
(1997)
Biochemistry
36,
13357-13364
5.
Flohe, L.,
Hecht, H. J.,
and Steinert, P.
(1999)
Free Radic. Biol. Med.
27,
966-984
6.
Montemartini, M.,
Kalisz, H. M.,
Hecht, H. J.,
Steinert, P.,
and Flohe, L.
(1999)
Eur. J. Biochem.
264,
516-524
7.
Chae, H. Z.,
Robison, K.,
Poole, L. B.,
Church, G.,
Storz, G.,
and Rhee, S. G.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7017-7021
8.
Kang, S. W.,
Baines, I. C.,
and Rhee, S. G.
(1998)
J. Biol. Chem.
273,
6303-6311
9.
Kang, S. W.,
Chae, H. Z.,
Seo, M. S.,
Kim, K.,
Baines, I. C.,
and Rhee, S. G.
(1998)
J. Biol. Chem.
273,
6297-6302
10.
Jin, D. Y.,
Chae, H. Z.,
Rhee, S. G.,
and Jeang, K. T.
(1997)
J. Biol. Chem.
272,
30952-30961
11.
Matsumoto, A.,
Okado, A.,
Fujii, T.,
Fujii, J.,
Egashira, M.,
Niikawa, N.,
and Taniguchi, N.
(1999)
FEBS Lett.
443,
246-250
12.
Chae, H. Z.,
Kim, H. J.,
Kang, S. W.,
and Rhee, S. G.
(1999)
Diabetes Res. Clin. Pract.
45,
101-112
13.
Chae, H. Z.,
Uhm, T. B.,
and Rhee, S. G.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7022-7026
14.
Choi, H. J.,
Kang, S. W.,
Yang, C. H.,
Rhee, S. G.,
and Ryu, S. E.
(1998)
Nat. Struct. Biol.
5,
400-406
15.
Hirotsu, S.,
Abe, Y.,
Okada, K.,
Nagahara, N.,
Hori, H.,
Nishino, T.,
and Hakoshima, T.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
12333-12338
16.
Altschul, S. F.,
Madden, T. L.,
Schaffer, A. A.,
Zhang, J.,
Zhang, Z.,
Miller, W.,
and Lipman, D. J.
(1997)
Nucleic Acids Res.
25,
3389-3402
17.
Chae, H. Z.,
Kang, S. W.,
and Rhee, S. G.
(1999)
Methods Enzymol.
300,
219-226
18.
Jeong, J. S.,
Kwon, S. J.,
Kang, S. W.,
Rhee, S. G.,
and Kim, K.
(1999)
Biochemistry
38,
776-783
19.
Yamashita, H.,
Avraham, S.,
Jiang, S.,
London, R.,
Van Veldhoven, P. P.,
Subramani, S.,
Rogers, R. A.,
and Avraham, H.
(1999)
J. Biol. Chem.
274,
29897-29904
20.
Lee, J.,
Spector, D.,
Godon, C.,
Labarre, J.,
and Toledano, M. B.
(1999)
J. Biol. Chem.
274,
4537-4544
21.
Luthman, M.,
and Holmgren, A.
(1982)
J. Biol. Chem.
257,
6686-6690
22.
Kim, K.,
Rhee, S. G.,
and Stadtman, E. R.
(1985)
J. Biol. Chem.
260,
15394-15397
23.
Velier, J.,
Kim, M.,
Schwarz, C.,
Kim, T. W.,
Sapp, E.,
Chase, K.,
Aronin, N.,
and DiFiglia, M.
(1998)
Exp. Neurol.
152,
34-40
24.
Webber, K. O.,
and Hajra, A. K.
(1993)
Arch. Biochem. Biophys.
300,
88-97
25.
Guyton, K. Z.,
Liu, Y.,
Gorospe, M.,
Xu, Q.,
and Holbrook, N. J.
(1996)
J. Biol. Chem.
271,
4138-4142
26.
del Arco, P. G.,
Martinez-Martinez, S.,
Calvo, V.,
Armesilla, A. L.,
and Redondo, J. M.
(1996)
J. Biol. Chem.
271,
26335-26340
27.
Knoops, B.,
Clippe, A.,
Bogard, C.,
Arsalane, K.,
Wattiez, R.,
Hermans, C.,
Duconseille, E.,
Falmagne, P.,
and Bernard, A.
(1999)
J. Biol. Chem.
274,
30451-30458
28.
Watabe, S.,
Kohno, H.,
Kouyama, H.,
Hiroi, T.,
Yago, N.,
and Nakazawa, T.
(1994)
J. Biochem. (Tokyo)
115,
648-654
29.
Spyrou, G.,
Enmark, E.,
Miranda-Vizuete, A.,
and Gustafsson, J.
(1997)
J. Biol. Chem.
272,
2936-2941
30.
Lee, S. R.,
Kim, J. R.,
Kwon, K. S.,
Yoon, H. W.,
Levine, R. L.,
Ginsburg, A.,
and Rhee, S. G.
(1999)
J. Biol. Chem.
274,
4722-4734
31.
Lo, Y. Y.,
and Cruz, T. F.
(1995)
J. Biol. Chem.
270,
11727-11730
32.
Sundaresan, M., Yu, Z. X.,
Ferrans, V. J.,
Irani, K.,
and Finkel, T.
(1995)
Science
270,
296-299
33.
Gotoh, Y.,
and Cooper, J. A.
(1998)
J. Biol. Chem.
273,
17477-17482
34.
Saitoh, M.,
Nishitoh, H.,
Fujii, M.,
Takeda, K.,
Tobiume, K.,
Sawada, Y.,
Kawabata, M.,
Miyazono, K.,
and Ichijo, H.
(1998)
EMBO J.
17,
2596-2606
35.
Fisher, A. B.,
Dodia, C.,
Manevich, Y.,
Chen, J. W.,
and Feinstein, S. I.
(1999)
J. Biol. Chem.
274,
21326-21334
36.
Peshenko, I. V.,
Novoselov, V. I.,
Evdokimov, V. A.,
Nikolaev, Y. V.,
Kamzalov, S. S.,
Shuvaeva, T. M.,
Lipkin, V. M.,
and Fesenko, E. E.
(1998)
Free Radic. Biol. Med.
25,
654-659
37.
Thompson, J. D.,
Gibson, T. J.,
Plewniak, F.,
Jeanmougin, F.,
and Higgins, D. G.
(1997)
Nucleic Acids Res.
25,
4876-4882
38.
Wang, X.,
Martindale, J. L.,
Liu, Y.,
and Holbrook, N. J.
(1998)
Biochem. J.
333,
291-300
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. He, J. Cai, Y.-M. Go, J. M. Johnson, W. D. Martin, J. M. Hansen, and D. P. Jones Identification of Thioredoxin-2 as a Regulator of the Mitochondrial Permeability Transition Toxicol. Sci., September 1, 2008; 105(1): 44 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kubo, N. Fatma, Y. Akagi, D. R. Beier, S. P. Singh, and D. P. Singh TAT-mediated PRDX6 protein transduction protects against eye lens epithelial cell death and delays lens opacity Am J Physiol Cell Physiol, March 1, 2008; 294(3): C842 - C855. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pollak, M. Niere, and M. Ziegler NAD Kinase Levels Control the NADPH Concentration in Human Cells J. Biol. Chem., November 16, 2007; 282(46): 33562 - 33571. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Cumming, R. Dargusch, W. H. Fischer, and D. Schubert Increase in Expression Levels and Resistance to Sulfhydryl Oxidation of Peroxiredoxin Isoforms in Amyloid beta-Resistant Nerve Cells J. Biol. Chem., October 19, 2007; 282(42): 30523 - 30534. [Abstract] [Full Text] [PDF] |
||||
![]() |
|